NO311784B1 - Anvendelse av 2,4-diaminopyrimidin-3-oksyd eller et salt derav for fremstilling av et farmasöytisk preparat for behandlingav maturasjons- og struktureringsforstyrrelser av kollagen - Google Patents
Anvendelse av 2,4-diaminopyrimidin-3-oksyd eller et salt derav for fremstilling av et farmasöytisk preparat for behandlingav maturasjons- og struktureringsforstyrrelser av kollagen Download PDFInfo
- Publication number
- NO311784B1 NO311784B1 NO19971182A NO971182A NO311784B1 NO 311784 B1 NO311784 B1 NO 311784B1 NO 19971182 A NO19971182 A NO 19971182A NO 971182 A NO971182 A NO 971182A NO 311784 B1 NO311784 B1 NO 311784B1
- Authority
- NO
- Norway
- Prior art keywords
- acid
- preparation
- dpo
- use according
- collagen
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 108010035532 Collagen Proteins 0.000 title claims abstract description 20
- 102000008186 Collagen Human genes 0.000 title claims abstract description 20
- 229920001436 collagen Polymers 0.000 title claims abstract description 20
- 150000003839 salts Chemical class 0.000 title claims abstract description 11
- 230000035800 maturation Effects 0.000 title claims abstract description 9
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 239000013543 active substance Substances 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 229960000448 lactic acid Drugs 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 229940098895 maleic acid Drugs 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229960001367 tartaric acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229950002929 trinitrophenol Drugs 0.000 claims description 2
- 230000005070 ripening Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 5
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 16
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 16
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 229960003632 minoxidil Drugs 0.000 description 10
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 9
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- -1 hydroxylysyl residues Chemical group 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- DHVJQUFZGZOFFY-UHFFFAOYSA-N (6-amino-2-imino-4-piperidin-1-ylpyrimidin-1-yl) hydrogen sulfate Chemical compound N=C1N(OS(O)(=O)=O)C(N)=CC(N2CCCCC2)=N1 DHVJQUFZGZOFFY-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229960000841 minoxidil sulfate Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000815 N-oxide group Chemical group 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001302 tertiary amino group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- RYDUZJFCKYTEHX-UHFFFAOYSA-N 2-(2-propan-2-yl-2,3-dihydro-1h-inden-5-yl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=C2CC(C(C)C)CC2=C1 RYDUZJFCKYTEHX-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical class COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000055207 HMGB1 Human genes 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- 229910052791 calcium Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229950000704 isoprofen Drugs 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 108010029843 preprocollagen Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical group NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9411133A FR2724561B1 (fr) | 1994-09-19 | 1994-09-19 | Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene |
| PCT/FR1995/001197 WO1996009048A1 (fr) | 1994-09-19 | 1995-09-19 | Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO971182D0 NO971182D0 (no) | 1997-03-14 |
| NO971182L NO971182L (no) | 1997-05-14 |
| NO311784B1 true NO311784B1 (no) | 2002-01-28 |
Family
ID=9467049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19971182A NO311784B1 (no) | 1994-09-19 | 1997-03-14 | Anvendelse av 2,4-diaminopyrimidin-3-oksyd eller et salt derav for fremstilling av et farmasöytisk preparat for behandlingav maturasjons- og struktureringsforstyrrelser av kollagen |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5846552A (fi) |
| EP (1) | EP0783307B1 (fi) |
| JP (1) | JP2945482B2 (fi) |
| KR (1) | KR100250939B1 (fi) |
| CN (1) | CN1070702C (fi) |
| AT (1) | ATE213414T1 (fi) |
| AU (1) | AU691336B2 (fi) |
| BR (1) | BR9508841A (fi) |
| CA (1) | CA2199995C (fi) |
| CZ (1) | CZ284476B6 (fi) |
| DE (1) | DE69525539T2 (fi) |
| DK (1) | DK0783307T3 (fi) |
| ES (1) | ES2171550T3 (fi) |
| FI (1) | FI971127A0 (fi) |
| FR (1) | FR2724561B1 (fi) |
| HU (1) | HU223143B1 (fi) |
| MX (1) | MX9701996A (fi) |
| NO (1) | NO311784B1 (fi) |
| PL (1) | PL186385B1 (fi) |
| PT (1) | PT783307E (fi) |
| RU (1) | RU2153874C2 (fi) |
| WO (1) | WO1996009048A1 (fi) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69831186T2 (de) * | 1997-04-30 | 2006-06-08 | Jsr Corp. | Orientierungsschicht für Flüssigkristall und Verfahren zu ihrer Herstellung |
| US7763587B2 (en) | 2002-06-13 | 2010-07-27 | L'oreal S.A. | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process |
| US7326717B2 (en) | 2003-05-06 | 2008-02-05 | L'oreal | Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof |
| FR2871688B1 (fr) | 2004-06-16 | 2008-05-16 | Oreal | Procede pour favoriser la penetration d'un actif et composition permettant sa mise en oeuvre |
| US7300649B2 (en) | 2005-02-11 | 2007-11-27 | Genepharm, Inc. | Cosmetic and cosmeceutical compositions for restoration of skin barrier function |
| FR2902324B1 (fr) * | 2006-06-20 | 2009-04-03 | Oreal | Utilisation d'acide ellagique pour le traitement de la canitie |
| EP1897533A1 (en) * | 2006-09-08 | 2008-03-12 | Revotar Biopharmaceuticals AG | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions |
| EP1946756A1 (en) * | 2007-01-17 | 2008-07-23 | Revotar Biopharmaceuticals AG | Use of entacapone in cosmetic, dermatological and pharmaceutical compositions |
| BRPI0916690B1 (pt) | 2008-07-29 | 2022-04-12 | L'oreal | Uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição coméstica e/ou dermatólogica, método coméstico para tratar e/ou prevenir distúrbios estéticos do couro cabeludo em um indivíduo, processo cosmético para prevenir e/ou tratar uma condição de caspa do couro cabeludo, conjunto cosmético, e, uso cosmético de pelo menos uma quantidade eficaz de pelo menos um primeiro e um segundo agente cosmético ativo |
| FR2951938B1 (fr) | 2009-10-30 | 2012-01-06 | Oreal | Utilisation d'un extrait de punica granatum pour lutter contre la canitie |
| CN104398418A (zh) * | 2014-11-06 | 2015-03-11 | 陈爱华 | 一种防脱发护发素 |
| FR3130153A1 (fr) | 2021-12-15 | 2023-06-16 | L'oreal | Utilisation d’au moins un dérivé de pyrimidine 3-oxyde pour renforcer la fonction barrière de la peau |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049902A3 (en) * | 1980-10-15 | 1982-09-01 | Teijin Limited | Novel thiazolo(3,2-a)pyrimidines, derivatives thereof, processes for production thereof, and pharmaceutical use thereof |
| FR2644460A1 (fr) * | 1989-03-16 | 1990-09-21 | Oreal | Esters retinoiques de d-desosamine, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| LU87766A1 (fr) * | 1990-07-20 | 1992-03-11 | Oreal | Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre |
| CA2085954A1 (en) * | 1991-12-24 | 1993-06-25 | Klaus Weidmann | Substituted pyridine n-oxides, processes for their preparation, and their use |
-
1994
- 1994-09-19 FR FR9411133A patent/FR2724561B1/fr not_active Expired - Fee Related
-
1995
- 1995-09-19 EP EP95931260A patent/EP0783307B1/fr not_active Expired - Lifetime
- 1995-09-19 HU HU9701236A patent/HU223143B1/hu not_active IP Right Cessation
- 1995-09-19 CA CA002199995A patent/CA2199995C/fr not_active Expired - Fee Related
- 1995-09-19 BR BR9508841A patent/BR9508841A/pt not_active Application Discontinuation
- 1995-09-19 RU RU97106336/14A patent/RU2153874C2/ru not_active IP Right Cessation
- 1995-09-19 MX MX9701996A patent/MX9701996A/es not_active IP Right Cessation
- 1995-09-19 WO PCT/FR1995/001197 patent/WO1996009048A1/fr active IP Right Grant
- 1995-09-19 US US08/809,950 patent/US5846552A/en not_active Expired - Fee Related
- 1995-09-19 CN CN95195438A patent/CN1070702C/zh not_active Expired - Fee Related
- 1995-09-19 DE DE69525539T patent/DE69525539T2/de not_active Expired - Lifetime
- 1995-09-19 DK DK95931260T patent/DK0783307T3/da active
- 1995-09-19 PT PT95931260T patent/PT783307E/pt unknown
- 1995-09-19 ES ES95931260T patent/ES2171550T3/es not_active Expired - Lifetime
- 1995-09-19 AT AT95931260T patent/ATE213414T1/de not_active IP Right Cessation
- 1995-09-19 AU AU34765/95A patent/AU691336B2/en not_active Ceased
- 1995-09-19 PL PL95319279A patent/PL186385B1/pl not_active IP Right Cessation
- 1995-09-19 CZ CZ97842A patent/CZ284476B6/cs not_active IP Right Cessation
- 1995-09-19 JP JP8510645A patent/JP2945482B2/ja not_active Expired - Fee Related
- 1995-09-19 KR KR1019970701754A patent/KR100250939B1/ko not_active IP Right Cessation
-
1997
- 1997-03-14 NO NO19971182A patent/NO311784B1/no unknown
- 1997-03-18 FI FI971127A patent/FI971127A0/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5037643A (en) | Cosmetic composition | |
| NO311784B1 (no) | Anvendelse av 2,4-diaminopyrimidin-3-oksyd eller et salt derav for fremstilling av et farmasöytisk preparat for behandlingav maturasjons- og struktureringsforstyrrelser av kollagen | |
| JPH0363213A (ja) | 化粧品組成物 | |
| US4975441A (en) | Lactams, their synthesis and use in cosmetic compositions | |
| JP2006117700A (ja) | 抗グリケーション剤としての少なくとも１つのスノキ属植物の抽出物の使用 | |
| JPH04963B2 (fi) | ||
| KR20130032788A (ko) | 발모 촉진용 펩타이드 및 이의 용도 | |
| KR102083081B1 (ko) | 유데나필을 유효성분으로 포함하는 지방줄기세포의 발모 유도능 증진용 조성물 | |
| US5358714A (en) | Cosmetic composition | |
| JPH06128295A (ja) | 毛髪成長調節用組成物 | |
| US8080524B2 (en) | Agent for slowing hair loss and/or stimulating hair growth | |
| KR20050074592A (ko) | 벤조피란을 사용한 모발 성장의 자극 방법 | |
| AU628551B2 (en) | Cosmetic composition | |
| CA1336965C (en) | Cosmetic composition | |
| WO2002022115A2 (en) | Methods and compositions for treating nail fungus | |
| JPH0386811A (ja) | 化粧品組成物 | |
| JP5065635B2 (ja) | 新規ペプチド | |
| JP4498593B2 (ja) | 育毛剤組成物 | |
| KR20220161172A (ko) | 세노모르픽스용 또는 피부 노화 방지용 조성물 | |
| KR20210045908A (ko) | Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
| RU2504541C1 (ru) | 2-нитрогетерилтиоцианаты для лечения грибковых инфекций, фармацевтическая композиция для местного применения | |
| KR20160050898A (ko) | Atp를 함유하는 발모 및 육모 촉진용 조성물 | |
| JPH11139953A (ja) | パラメリア属植物抽出物を含有する組成物 |